Enfortumab
CAS No. 1448664-46-7
Enfortumab( —— )
Catalog No. M36881 CAS No. 1448664-46-7
Enfortumab is a monoclonal antibody against Nectin-4.Enfortumab can be used to synthesize antibody-drug couplings (enfortumab vedotin) and can also be used in conjunction with platinum compounds to study uroepithelial cancers.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 588 | In Stock |
|
| 10MG | 943 | In Stock |
|
| 25MG | 1397 | In Stock |
|
| 50MG | 1841 | In Stock |
|
| 100MG | 2492 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameEnfortumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionEnfortumab is a monoclonal antibody against Nectin-4.Enfortumab can be used to synthesize antibody-drug couplings (enfortumab vedotin) and can also be used in conjunction with platinum compounds to study uroepithelial cancers.
-
DescriptionEnfortumab is a monoclonal antibody targeting Nectin-4. Enfortumab can used for researching urothelial cancer.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorADC Antibody
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1448664-46-7
-
Formula WeightApproximately 143.9 kDa.
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Rosenberg JE, et al. Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy. J Clin Oncol. 2019;37(29):2592-2600.
molnova catalog
related products
-
PCLX-001
PCLX-001 is a small-molecule compound that acts as an orally active inhibitor of N-myristoyltransferase (NMT), specifically targeting NMT1 and NMT2 with IC50 values of 5 nM and 8 nM, respectively.
-
AGRP (25-51)
AGRP (25-51)
-
Ginkgolic acid C13:0
Ginkgolic acid C13: exhibits the highest α-glucosidase inhibitory activity.
Cart
sales@molnova.com